Almarai Co.

The Strong Momentum continues in Q3 2020, while Future Concerns Remai

In line with our expectations for Q3 2020, Almarai was able to achieve an 8% Y-o-Y increase in revenue despite the tripling of the VAT last July. Moreover, EBIT margin remained relatively flat despite COVID- 19 related expenses in addition to alfalfa costs and Juice expenses. The growth in food service channels following the easing of restrictions, provided Almarai with some relief during the quarter, allowing the company to maintain its strong momentum in Q3 2020.

During Q3 2020, Almarai's revenues grew by around 8% Y-o-Y from SAR3,573mn in Q3 2019 to SAR3,863mn in Q3 2020. Despite the increase in the VAT from 5% to 15% on July, the company's revenue increased during the quarter on the back of Dairy & Juice sales that increased Y-o-Y by 9%, mainly through higher food and LLD exports sales (From SAR2,553mn in Q3 2019 to SAR2,770mn in Q3 2020). It is worth mentioning that during the quarter, food sales recorded a +15% Y-o-Y, while LLD sales grew by +21% Y-o-Y. Moreover, line with our previous expectation, Poultry sales also increased in by +7% Y-o-Y from SAR489mn in Q3 2019 to SAR524mn in Q3 2020 as a result of the reopening of restaurants which boosted food services channel growth. On the other hand, Bakery sales dropped by -8% Y-o-Y during the quarter due to single-serve impact.

Similar revenue, COGS increased during the quarter by 10% Y-o-Y from SAR2,129mn in Q3 2019 to SAR2,348mn in Q3 2020. Nevertheless, Almarai's gross margin remained almost flat Y-o-Y, posting 39% in Q3 2020.

SG&A increased during the quarter by 8% Y-o-Y from SAR674mn Q3 2019 to SAR726mn in Q3 2020 in line with revenue and volume growth in addition to higher labor costs due to the pandemic. Moreover, EBIT was slightly impacted by the increase in operating costs, which was mainly due to higher juice ingredients (sugar free recipe), feed (imported alfalfa) and labor (due to COVID-19) costs, in addition to, higher depreciation and losses in the Dairy and Juice segment. However, EBIT margin remained flat Y-o-Y, sitting at 19% in Q3 2020.

Finance charges decreased by 10% Y-o-Y, from SAR131mn in Q3 2019 to SAR91mn in Q3 2020, which is mainly attributed to lower interest rates as well as lower debt levels.

Consequently, net income for the period increased by around 7% from SAR582mn in Q3 2019 to SAR621mn in Q3 2020, meanwhile, net income margin remained flat at 16% in Q3 2020.

Almarai's is still maintaining their strict Capex send in line with their current capacity, limiting their Capex budget to maintenance. Moreover, the company's cash in hand is SAR591mn for Q3 2020, with no additional funding required until the end of the year.

It is undoubtedly that Almarai showed resilience in the time of the pandemic, as it maintained 1st rank across all product categories except UHT milk, however, the challenge remains in the limited growth potential. Moreover, the company will have to go through price adjustments and product realization post VAT, which might negatively impact demand, especially coupled with the expat exodus and the significant decline in the consumers' disposable income. Finally, higher operational costs, including high depreciation and overheads in Egypt continue to pressure the company's margins.

While the pandemic seems to have had a minimal impact on Almarai, the concern remains in the anticipated market shift post the pandemic and how this shift will materialize.

We remaining our 52 weeks target price SAR49/share while maintaining our **NEUTRAL** recommendation.




II October 2020
Neutral
Neutral
SAR54.1
SAR49.0
(9.5%)
Pass


Key Financial Ratios

Ratio	Q3 2020	Q2 2020	Q3 2019
Revenue Growth	-5.4%	8.4%	-5.1%
Gross Margin	39.2%	37.6%	40.4%
EBIT Margin	19.4%	18.6%	20.9%
Net Margin	16.1%	15.2%	16.3%

Key Financial Results (Q3 2020)



Share Price Performance



Financial Projection

Guide to Ratings

Buy	An upside potential of more than 20% in 52-week period
Overweight	An upside Potential of more than 10% in 52-week period
Neutral	Will stay in the range of it value (up/down 10%) in a 52-week period
Underweight	A downside potential of more than 10% in 52-week period
Sell	A downside potential of more than 20% in 52-week period

Itqan Capital

The HQBP Tower, Corniche Road, Al Shatea District, PO Box 8021, Jeddah 21482, Kingdom of Saudi Arabia Tel: 966 12 510 6030 Fax: 966 12 510 6033 info@itqancapital.com www.itqancapital.com

Disclaimer

This research document has been prepared by Itgan Capital Company ("Itgan Capital"), Saudi Arabia. It has been prepared for the general use of Itgan Capital's clients and may not be redistributed, retransmitted or disclosed, in whole or in part, or in any form or manner, without the express written consent of Itgan Capital. Receipt and review of this research document constitute your agreement not to redistribute, retransmit, or disclose to others the contents, opinions, conclusion, or information contained in this document prior to public disclosure of such information by Itgan Capital. The information contained was obtained from various public sources believed to be reliable, but we do not guarantee its accuracy. Itgan Capital makes no representations or warranties (express or implied) regarding the data and information provided and Itgan Capital does not represent that the information content of this document is complete, or free from any error, not misleading, or fit for any particular purpose. This research document provides general information only. Neither the information nor any opinion expressed constitutes an offer or an invitation to make an offer, to buy or sell any securities or other investment products related to such securities or investments. It is not intended to provide personal investment advice and it does not take into account the specific investment objectives, financial situation and the particular needs of any specific person who may receive this document. Investors should seek financial, legal or tax advice regarding the appropriateness of investing in any securities, other investment or investment strategies discussed or recommended in this document and should understand that statements regarding future prospects may not be realized. Investors should note that income from such securities or other investments, if any, may fluctuate and that the price or value of such securities and investments may rise or fall. Fluctuations in exchange rates could have adverse effects on the value of or price of, or income derived from, certain investments. Accordingly, investors may receive back less than originally invested. Itgan Capital or its officers or one or more of its affiliates (including research analysts) may have a financial interest in securities of the issuer(s) or related investments, including long or short positions in securities, warrants, futures, options, derivatives, or other financial instruments. Itgan Capital or its affiliates may from time to time perform investment banking or other services for, solicit investment banking or other business from, any company mentioned in this research document. Itqan Capital, together with its affiliates and employees, shall not be liable for any direct, indirect or consequential loss or damages that may arise, directly or indirectly, from any use of the information contained in this research document. This research document and any recommendations contained are subject to change without prior notice. Itgan Capital assumes no responsibility to update the information in this research document. Neither the whole nor any part of this research document may be altered, duplicated, transmitted or distributed in any form or by any means. This research document is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or which would subject Itqan Capital or any of its affiliates to any registration or licensing requirement within such jurisdiction.

Itqan Capital is licensed by the Saudi Arabian Capital Market Authority, License No.07058-37 and CR No.4030167335